Merck’s WELIREG Gains EU Approval for Advanced Kidney and VHL Tumors

Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has achieved a milestone with the European Commission’s conditional approval of WELIREG® (belzutifan). This first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor is now authorized for adult patients with von Hippel-Lindau (VHL) disease who require treatment for certain tumors, as well as those with advanced clear cell renal cell carcinoma (RCC) that has progressed after multiple prior treatments. The approval is based on results from the LITESPARK-004 and LITESPARK-005 trials, which demonstrated promising outcomes in patients with limited treatment options.

For patients battling these complex conditions, WELIREG represents a beacon of hope. It is the first systemic therapy available for certain VHL disease-associated tumors in the EU, offering a non-surgical option where localized procedures are unsuitable. Additionally, its approval for advanced RCC provides a much-needed alternative for those whose disease has progressed despite standard treatments. “This approval is a significant step forward,” said Dr. Marjorie Green, senior vice president of oncology at Merck Research Laboratories. “We are committed to delivering innovative therapies to patients who need them most.”